Seminars in Oncology Nursing
Volume 22, Issue 2 , Pages 90-96 , May 2006

Cutaneous T-Cell Lymphoma

  • Robin Gemmill

      Affiliations

    • Corresponding Author InformationAddress correspondence to Robin Gemmill, MSN, RN, CNS, CWOCN, City of Hope National Medical Center, Duarte, CA

References 

  1. Girardi M , Heald PW , Wilson LD . The pathogenesis of mycosis fungoides . N Engl J Med . 2004;350:1978–1988
  2. Duvic M , Edelson R . Cutaneous T-cell lymphoma . J Am Acad Dermatol . 2004;51(suppl):S43–S45
  3. Willemze R . Cutaneous T-cell lymphoma (Epidemiology, etiology, and classification) . Leuk Lymphoma . 2003;44(suppl 3):S49–S54
  4. Smith BD , Wilson LD . Management of mycosis fungoides. Part 1. Diagnosis, staging, and prognosis . Oncology . 2003;17:1281–1288
  5. Lymphoma Information Network. Available at: http://www.lymphomainfo.net (accessed March 31, 2005).
  6. Diamandidou E , Cohen PR , Kurzrock R . Mycosis fungoides and Sezary syndrome . Blood . 1996;88:2395–2409
  7. Siegel RS , Pandolfino T , Guitart J , et al.   Primary cutaneous T-cell lymphoma (Review and current concepts) . J Clin Oncol . 2000;18:2908–2925
  8. Berger CL , Hanlon D , Kanada D , et al.   The growth of cutaneous T-cell lymphoma is stimulated by immature dendritic cells . Blood . 2002;99:2929–2939
  9. Fung MA , Murphy MJ , Hoss DM , et al.   Practical evaluation and management of cutaneous lymphoma . J Am Acad Dermatol . 2002;46:325–360
  10. Herne KL , Talpur R , Breuer-McHam J , et al.   Cytomegalovirus seropositivity is significantly associated with mycosis fungoides and Sezary syndrome . Blood . 2003;101:2132–2136
  11. Ni X , Hazarika P , Zhang C , et al.   Fas ligand expression by neoplastic T lymphocytes medicates elimination of CD8+ cytotoxic T lymphocytes in mycosis fungoides (A potential mechanism of tumor immune escape) . Clin Cancer Res . 2001;7:2682–2692
  12. Willemze R , Jaffe ES , Burg G , et al.   WHO-EORTC classification for cutaneous lymphomas . Blood . 2005;105:3768–3785
  13. Morales-Suarez-Varela M , Olsen J , Johansen P , et al.   Occupational risk factors for mycosis fungoides (A European multicenter case-control study) . J Occup Environ Med . 2004;46:205–211
  14. Samuleson E . Cutaneous T-cell lymphomas . Semin Oncol Nurs . 1998;14:293–301
  15. Foss F . Mycosis fungoides and the Sezary syndrome . Curr Opin Oncol . 2004;16:421–428
  16. Manson S , Porter C . Lymphomas . In:  Yarbro CH ,  Frogge MH ,  Goodman M editor. Cancer Nursing (Principles and Practice) . Ed 6. Boston, MA: Jones and Bartlett; 2005;p. 1414–1459
  17. Foulc P , N’Guyen JM , Dreno B . Prognostic factors in Sezary syndrome of 28 patients . Br J Dermatol . 2003;149:1152–1158
  18. Bunn PA , Lamberg SI . Report of the committee on staging and classification of cutaneous T-cell lymphomas . Cancer Treat Rep . 1979;63:725–728
  19. Smith BD , Wilson LD . Management of mycosis fungoides. Part 2. Treatment . Oncology . 2003;17:1419–1428
  20. Hobbs L , Doughty D . Mycosis fungoides (A wound care challenge) . J Wound Ostomy Cont Nurs . 2004;31:95–97
  21. Demierre MF , Tien A , Miller D . Health-related quality-of-life assessment in patients with cutaneous T-cell lymphoma . Arch Dermatol . 2005;141:325–330
  22. Soung J , Muigai W , Amin N , et al.   Chart review of patients with early stage mycosis fungoides treated with psoralen plus UVA (PUVA) . J Drugs Dermatol . 2005;4:290–294
  23. McGinnis KS , Junkins-Hopkins JM , Crawford G , et al.   Low-dose oral bexarotene in combination with low-dose interferon alfa in the treatment of cutaneous T-cell lymphoma (Clinical synergism and possible immunologic mechanisms) . Am Acad Dermatol . 2004;50:375–379
  24. Edelson R . Cutaneous T cell lymphoma (The helping hand of dendritic cells) . Ann NY Acad Sci . 2001;941:1–11
  25. Kuzel TM , Junghans R , Foss FM . Novel agents for cutaneous T-cell lymphoma . Hematol Oncol Clin North Am . 2003;17:1459–1466
  26. Apissanthanarax N , Talpur R , Ward S , et al.   Tazarotene 0.1% gel for refractory mycosis fungoides lesions (An open-label pilot study) . J Am Acad Dermatol . 2004;50:600–607
  27. Guitart J , Wickless SC , Oyama Y , et al.   Long-term remission after allogenic hematopoietic stem cell transplantation for refractory cutaneous T-cell lymphoma . Arch Dermatol . 2002;138:1359–1365
  28. Fore-Pfliger J . The epidermal skin barrier (Implications for the wound care practitioner, Part II) . Adv Skin Wound Care . 2004;17:480–488

PII: S0749-2081(06)00014-3

doi: 10.1016/j.soncn.2006.01.005

Seminars in Oncology Nursing
Volume 22, Issue 2 , Pages 90-96 , May 2006

Article Tools